29 August 2017

Oxford BioMedica: Stuart Paynter starts as new Chief Financial Officer 

jjj

Oxford, UK – 29 August 2017: Oxford BioMedica plc (LSE: OXB) (“OXB” or “the Group”), a leading gene and cell therapy group, confirms that, as previously announced on 28 February 2017, Stuart Paynter today joins the Group as Chief Financial Officer and member of the Board of Directors. Tim Watts, the outgoing Chief Financial Officer, will remain with the Group until Friday 29 September 2017, at which point he will step down from the Board of Directors and leave the Group.

- Ends -

 

For further information, please contact:

Oxford BioMedica plc:  Tel: +44 (0)1865 783 000

John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tim Watts

Financial PR Enquiries:  Tel: +44 (0)20 3709 5700

Mary-Jane Elliott / Matthew Neal / Philippa Gardner / Laura Thornton
Consilium Strategic Communications

 

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.  Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners.  The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.  The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.  Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people.  Further information is available at www.oxfordbiomedica.co.Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.  Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners.  The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.  The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.  Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people.  Further information is available at www.oxfordbiomedica.co.uk.


Back to previous page